Department of Dermatology, University of Wisconsin, Madison, Wisconsin, USA.
William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin, USA.
Photochem Photobiol. 2024 Jul-Aug;100(4):910-922. doi: 10.1111/php.13951. Epub 2024 Apr 16.
Metastatic melanoma is an aggressive skin cancer with high mortality and recurrence rates. Despite the clinical success of recent immunotherapy approaches, prevailing resistance rates necessitate the continued development of novel therapeutic options. Photoimmunotherapy (PIT) is emerging as a promising immunotherapy strategy that uses photodynamic therapy (PDT) to unleash systemic immune responses against tumor sites while maintaining the superior tumor-specificity and minimally invasive nature of traditional PDT. In this review, we discuss recent advances in PIT and strategies for the management of melanoma using PIT. PIT can strongly induce immunogenic cell death, inviting the concomitant application of immune checkpoint blockade or adoptive cell therapies. PIT can also be leveraged to selectively remove the suppressive immune populations associated with immunotherapy resistance. The modular nature of PIT therapy design combined with the potential for patient-specific antigen selection or drug co-delivery makes PIT an alluring option for future personalized melanoma care.
转移性黑色素瘤是一种侵袭性皮肤癌，死亡率和复发率较高。尽管最近的免疫疗法取得了临床成功，但普遍存在的耐药率仍需要继续开发新的治疗选择。光免疫疗法（PIT）作为一种有前途的免疫疗法策略正在兴起，它利用光动力疗法（PDT）在保持传统 PDT 的优异肿瘤特异性和微创性的同时，引发针对肿瘤部位的全身免疫反应。在这篇综述中，我们讨论了 PIT 的最新进展以及使用 PIT 治疗黑色素瘤的策略。PIT 可以强烈诱导免疫原性细胞死亡，从而可以同时应用免疫检查点抑制剂或过继细胞疗法。PIT 还可以用于选择性去除与免疫治疗耐药相关的抑制性免疫群体。PIT 治疗设计的模块化性质以及患者特异性抗原选择或药物共递送的潜力，使 PIT 成为未来个性化黑色素瘤治疗的诱人选择。
